# Drug-drug Interaction Study of Lemborexant as an Adjunctive Treatment for Buprenorphine/Naloxone for Opioid Use Disorder

> **NCT04818086** · PHASE1,PHASE2 · COMPLETED · sponsor: **Virginia Commonwealth University** · enrollment: 18 (actual)

## Conditions studied

- Drug Interaction
- Analgesics
- Opioid Use Disorder

## Interventions

- **DRUG:** Lemborexant
- **DRUG:** Placebo
- **DRUG:** Buprenorphine-naloxone

## Key facts

- **NCT ID:** NCT04818086
- **Lead sponsor:** Virginia Commonwealth University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-03
- **Primary completion:** 2023-04-20
- **Final completion:** 2023-04-20
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2024-11-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04818086

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04818086, "Drug-drug Interaction Study of Lemborexant as an Adjunctive Treatment for Buprenorphine/Naloxone for Opioid Use Disorder". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04818086. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*